Maxigen Biotech Inc.

1783

TW0001783009

Personal Products

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 03/06/2024 am IST			5-day change	1st Jan Change
42.6 ^TWD	+0.83%		+0.59%	-11.98%

06/05	Maxigen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/05	Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2023 to December 31, 2023	CI

Maxigen Biotech Inc. Announces Resignation of Yu, Yi Hua as Financial Officer and Accounting Officer

March 21, 2022 at 06:26 pm IST

Maxigen Biotech Inc. announced resignation of YU, YI HUA as financial officer and accounting officer, effective from March 21, 2022.

Latest news about Maxigen Biotech Inc.

Maxigen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05	CI
Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2023 to December 31, 2023	03/05	CI
Maxigen Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Maxigen Biotech Inc.(TWSE:1783) added to S&P Global BMI Index	18/23/18	CI
Maxigen Biotech Inc. Declares Dividend, Payable on October 12, 2023	23/23/23	CI
Maxigen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/23/26	CI
Maxigen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2022 to December 31, 2022	03/23/03	CI
Maxigen Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Maxigen Biotech Inc. Announces Executive Changes	22/23/22	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year to Date Ended December 2022	06/23/06	CI
Maxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting Officer	29/22/29	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year to Date Ended November 2022	06/22/06	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year to Date Ended October 2022	07/22/07	CI
Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/22/25	CI
Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year-To-Date Ended September 2022	05/22/05	CI
Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year-to-Date Ended July 2022	09/22/09	CI
Maxigen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/22/03	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year-To-Date Ended June 2022	07/22/07	CI
Maxigen Biotech Inc. Announces Consolidated Revenue Results for the Month and Year to Date Ended May 2022	06/22/06	CI
Maxigen Biotech Inc. Announces Resignation of Lu Min Hsuan as Chief Internal Auditor	13/22/13	CI
Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended April 2022	06/22/06	CI
Maxigen Biotech Inc. Approves the Appointment of You Wan-How, Manager as Financial Officer and Accounting Officer	03/22/03	CI
Maxigen Biotech Inc. Appoints Lin Yung-Hsiang to Nomination Committee	03/22/03	CI

MAXIGEN BIOTECH INC. is a Taiwan-based company principally engaged in the manufacture and sales of biological products, the wholesale of all kinds of medical equipment, medicines, foods, masks, skin care products, as well as the manufacture and sales of chemical materials. The Company operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.

Sector

Personal Products

Calendar

13/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Cosmetics & Perfumes

	1st Jan change	Capi.
MAXIGEN BIOTECH INC.	-11.98%	116M
KAO CORPORATION	+20.57%	20.37B
GALDERMA GROUP AG	0.00%	19.29B
SHISEIDO COMPANY, LIMITED	+17.45%	12.64B
COTY INC.	-17.91%	8.94B
AMOREPACIFIC CORPORATION	+29.10%	8.62B
PROYA COSMETICS CO.,LTD.	+11.17%	5.93B
NATURA &CO HOLDING S.A.	-10.78%	3.92B
INTER PARFUMS, INC.	-15.28%	3.84B
KOSÉ CORPORATION	-0.80%	3.77B